Results 31 to 40 of about 32,846 (250)

The management of type 2 diabetes with fixed‐ratio combination insulin degludec/liraglutide (IDegLira) versus basal‐bolus therapy (insulin glargine U100 plus insulin aspart): a short‐term cost‐effectiveness analysis in the UK setting [PDF]

, 2018
Aim: To evaluate the cost‐effectiveness of IDegLira versus basal‐bolus therapy (BBT) with insulin glargine U100 plus up to 4 times daily insulin aspart for the management of type 2 diabetes in the UK.
ADVANCE Collaborative Group, American Diabetes Association Consensus Panel, Anderson, Bagust, Bagust, Billings, Blak, Boye, Chubb, Control Group, Currie, Donnelly, Duckworth, Evans, Forst, Gaede, Gaede, Giugliano, Grandy, Hammer, Holman, Hunt, Hunt, Hunt, Inzucchi, Ismail-Beigi, Johnston, Lee, Matza, McCabe, Meneghini, Mezquita-Raya, National Institute for Health and Care Excellence (NICE), Nauck, Parekh, Peyrot, Peyrot, Ridderstråle, Russell-Jones, Shi, Stettler, The Forum for Injection Technique (FIT), TREND-UK, UK Prospective Diabetes Study (UKPDS) Group, UK Prospective Diabetes Study (UKPDS) Group, Walz, Wang, Wild   +47 more
core   +1 more source

Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

BMC Endocrine Disorders, 2022
Background The efficacy of liraglutide to treat type 2 diabetic nephropathy (T2DN) remains controversial. Thus, we conducted this meta-analysis to systematically evaluate the clinical effect of liraglutide on T2DN patients.
Niroj Mali, Feng Su, Jie Ge, Wen Xing Fan, Jing Zhang, Jingyuan Ma   +5 more
doaj   +1 more source

Gut microbiota mediates positive effects of liraglutide on dyslipidemia in mice fed a high-fat diet

Frontiers in Nutrition, 2022
Except for improving glycemic control, liraglutide, one of the glucagon-like peptide-1 receptor agonists, has exerted promising therapeutic effects for dyslipidemia.
Li Zhao, Yue Qiu, Panpan Zhang, Xunan Wu, Zhicong Zhao, Xia Deng, Ling Yang, Dong Wang, Guoyue Yuan   +8 more
doaj   +1 more source

Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes [PDF]

, 2017
Postprandial hyperglycemia remains a challenge in type 1 diabetes (T1D) due, in part, to dysregulated increases in plasma glucagon levels after ...
Carria, Lori, Cengiz, Eda, Galderisi, Alfonso, Sherr, Jennifer, Tamborlane, William, Tichy, Eileen, Vanname, Michelle, Weinzimer, Stuart, Weyman, Kate, Zgorski, Melinda   +9 more
core   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Liraglutide Ameliorates the Development of Periodontitis

Journal of Diabetes Research, 2020
Periodontitis is one of the diabetic complications due to its high morbidity and severity in patients with diabetes. The prevention of periodontitis is especially important in diabetic patients because the relationship between diabetes and periodontitis ...
Noritaka Sawada, Kei Adachi, Nobuhisa Nakamura, Megumi Miyabe, Mizuho Ito, Shuichiro Kobayashi, Shin-ichi Miyajima, Yuki Suzuki, Takeshi Kikuchi, Makoto Mizutani, Taku Toriumi, Masaki Honda, Akio Mitani, Tatsuaki Matsubara, Keiko Naruse   +14 more
doaj   +1 more source

Liraglutide Attenuates Hepatic Ischemia–Reperfusion Injury by Modulating Macrophage Polarization

Frontiers in Immunology, 2022
Ischemia-reperfusion injury (IRI) is a common complication associated with liver surgery, and macrophages play an important role in hepatic IRI. Liraglutide, a glucagon-like peptide-1 (GLP-1) analog primarily used to treat type 2 diabetes and obesity ...
Shang-Lin Li, Shang-Lin Li, Zhi-Min Wang, Cong Xu, Cong Xu, Fu-Heng Che, Fu-Heng Che, Xiao-Fan Hu, Xiao-Fan Hu, Rui Cao, Rui Cao, Ya-Nan Xie, Ya-Nan Xie, Yang Qiu, Yang Qiu, Hui-Bo Shi, Hui-Bo Shi, Bin Liu, Bin Liu, Chen Dai, Chen Dai, Jun Yang, Jun Yang   +22 more
doaj   +1 more source

Glucagon-like peptide analogues for type 2 diabetes mellitus : systematic review and meta-analysis [PDF]

, 2010
Background Glucagon-like peptide (GLP-1) analogues are a new class of drugs used in the treatment of type 2 diabetes. They are given by injection, and regulate glucose levels by stimulating glucose-dependent insulin secretion and biosynthesis ...
Shyangdan, D. (Deepson), Royle, Pamela, Clar, C., Sharma, Pawana, Waugh, Norman   +4 more
core   +4 more sources

Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer's disease and type 2 diabetes [PDF]

, 2020
Background Both Alzheimer's disease (AD) and type 2 diabetes (T2D) share common pathological features including inflammation, insulin signaling alterations, or vascular damage.
Alves-Martinez, Pilar, Carranza-Naval, María José, García Alloza, Mónica, Herrera, Marta, Hierro Bujalance, Carmen, Infante-Garcia, Carmen, Lubián López, Simón Pedro, Marco González, Ángel José del, Suarez, Javier   +8 more
core   +1 more source

Effects of liraglutide on ANP secretion and cardiac dynamics

Endocrine Connections, 2023
To observe the effects of liraglutide (analog of glucagon-like peptide 1 (GLP-1)) on atrial natriuretic peptide (ANP) secretion and atrial dynamics, an ex vivo isolated rat atrial perfusion model was used to determine atrial ANP secretion and pulse ...
Shenghe Luo, Yunhui Zuo, Xiaotian Cui, Meiping Zhang, Honghua Jin, Lan Hong   +5 more
doaj   +1 more source

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources